Author Archives: Patricia Inacio, PhD

EU Grants Bardoxolone Orphan Drug Status as Potential Alport Therapy, Phase 3 Trial Enrolling

The European Commission (EC) has granted orphan drug status to bardoxolone methyl (bardoxolone)as a possible treatment for Alport syndrome, the therapy’s developer, Reata Pharmaceuticals, announced. Its effectiveness and safety are now being evaluated in a global clinical trial that’s enrolling patients with confirmed Alport syndrome and symptoms of kidney…

Recurrence of Kidney Inflammation a Risk Factor for Kidney Rejection After Transplant, Study Shows

In patients with acute kidney inflammation, also known as glomerulonephritis, recurrence of the disease is a significant factor underlying failed kidney transplants, a study suggests. The study, “Clinical Outcomes of Kidney Transplantation in Patients With Biopsy-Proven Glomerulonephritis,” was published in the journal Transplantation Proceedings. Clinical outcomes of patients with…

Reata’s Bardoxolone Methyl Benefits Patients with Chronic Kidney Disease, TSUBAKI Trial Shows

Kyowa Hakko Kirin, a partner company of Reata Pharmaceuticals, presented positive results from its TSUBAKI study showing that Reata’s investigational therapy bardoxolone methyl significantly improved kidney function in patients with chronic kidney disease (CKD) and type 2 diabetes. The presentation, “Bardoxolone Methyl Improved GFR Measured by Standard…

Create your own user feedback survey